Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ACTR087 + Rituximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ACTR087||ACTR-087|ACTR 087||ACTR087 is a chimeric construct consisting of the extracellular domain of CD16 linked to CD3zeta signaling and 41BB co-stimulatory domains delivered into human T-cells via gamma-retrovirus, which may lead to enhanced anti-tumor activity in combination with tumor-targeting antibodies (Blood 2016, 128(22):3512).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 21||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02776813||Phase I||ACTR087 + Rituximab||Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma||Completed||USA||0|